Lakefront Biotherapeutics reported EUR6.5M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
argenx SE USD 1.36B 240M Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Biogen USD 2.74B 490M Jun/2026
Genmab DKK 1.06B 36M Dec/2025
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
GRIFOLS EUR 1.87B 170M Jun/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Incyte USD 1.67B 400M Jun/2026
Merck EUR 5.13B 120M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
UCB EUR 4.25B 764M Dec/2025
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026